GlassScriptPhysician profile
Douglas W Mapel
NPI 1497730451
$125,131.79
in general payments reported to CMS, 2019-2025
31 companies · $17K in 2025
The $17K reported for 2025 was more than what 96% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,524 · 2020: $339 · 2021: $5,757 · 2022: $588 · 2023: $70K · 2024: $30K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $97K · Travel and Lodging: $11K · Food and Beverage: $5,420 · Consulting Fee: $2,695 · Education: $271 · Gift: $17.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $96,850.00 |
| Travel and Lodging | $10,670.38 |
| Food and Beverage | $5,420.23 |
| Consulting Fee | $2,695.00 |
| Education | $270.95 |
| Gift | $17.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $114,601.51 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,220.27 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Genentech USA, INC. | $2,761.34 | 2019-2023 | Xolair |
| Astrazeneca Uk Limited | $1,395.00 | 2024 | |
| Mylan Specialty L.P. | $668.75 | 2019-2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $664.09 | 2019-2025 | Tezspire, Fasenra, Imfinzi |
| Genzyme Corporation | $222.48 | 2020-2025 | |
| Actelion Pharmaceuticals US, INC. | $209.28 | 2020-2025 | Uptravi, Opsumit |
| Viatris Specialty LLC | $161.28 | 2025 | Yupelri |
| Mylan INC. | $126.89 | 2025 | Yupelri |
| Electromed, INC. | $112.77 | 2024-2025 | Smartvest |
| Merck Sharp & Dohme LLC | $103.03 | 2024-2025 | Zerbaxa |
| Inari Medical, INC. | $100.24 | 2022 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| Insmed, INC. | $91.35 | 2023-2025 | Arikayce, Brinsupri |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $86.42 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $74.15 | 2024-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $67.32 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $63.97 | 2021-2022 | |
| Baxter Healthcare | $55.09 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Abiomed | $35.55 | 2025 | |
| Covis Pharma Gmbh | $34.69 | 2022 | |
| Philips North America LLC | $34.36 | 2020-2024 | (8874) Incourage |
| United Therapeutics Corporation | $24.56 | 2023 | Tyvaso |
| Tactile Systems Technology INC | $22.96 | 2024 | Flexitouch Plus, Entre Plus |
| Shire North American Group INC | $21.57 | 2019 | |
| Pfizer INC. | $19.54 | 2019 | |
| Grifols USA, LLC | $19.10 | 2021 | |
| Gilead Sciences, INC. | $18.68 | 2025 | Veklury |
| Inogen, INC. | $15.60 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Mapel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.